Home > Newsletters > Drug Industry Daily > Authorized Generic Deals Are ‘Pay for Delay,’ FTC Tells Courts … Again
Drug Industry Daily
Oct. 10, 2012 | Vol. 11 No. 199
Authorized Generic Deals Are ‘Pay for Delay,’ FTC Tells Courts … Again
The FTC is challenging a GlaxoSmithKline (GSK)-Teva patent settlement deal, filing an amicus brief that argues authorized generic agreements fall under the category of pay-for-delay deals and are anticompetitive.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.